Sign Up Today and Learn More About A2 Biotherapeutics Stock
Invest in or calculate the value of your shares in A2 Biotherapeutics or other pre-IPO companies through EquityZen's platform.
A2 Biotherapeutics Stock (ATWB)
A2 Biotherapeutics develops novel medicines for serious illness.
About A2 Biotherapeutics Stock
Founded
2018
Headquarters
Westlake Village, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. We utilize an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.
A2 Biotherapeutics Press Mentions
Stay in the know about the latest news on A2 Biotherapeutics
ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc.
marketscreener • May 06, 2025
Engineered immune cells with receptor cross-talk
patents • May 04, 2025
Malignant Pleural Mesothelioma Market Poised for Growth Across the 7MM During the Study Period (2020–2034) Amid Advances in Immunotherapy and Targeted Drugs | DelveInsight
globenewswire • Apr 21, 2025
Compositions and methods for treating cancers with hla-a*03 loss of expression
patents • Apr 02, 2025
Immune cells with paired receptors and uses thereof
patents • Apr 02, 2025
A2 Biotherapeutics Management
Leadership team at A2 Biotherapeutics
Sr Director Technology
Han Xu
Independent Director
Madhavan Balachandran
Join now and verify your accreditation status to gain access to:
- A2 Biotherapeutics Current Valuation
- A2 Biotherapeutics Stock Price
- A2 Biotherapeutics Management
- Available deals in A2 Biotherapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- A2 Biotherapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- A2 Biotherapeutics Revenue and Financials
- A2 Biotherapeutics Highlights
- A2 Biotherapeutics Business Model
- A2 Biotherapeutics Risk Factors
- A2 Biotherapeutics Research Report from SACRA Research
Trading A2 Biotherapeutics Stock
How to invest in A2 Biotherapeutics stock?
Accredited investors can buy pre-IPO stock in companies like A2 Biotherapeutics through EquityZen funds. These investments are made available by existing A2 Biotherapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell A2 Biotherapeutics stock?
Shareholders can sell their A2 Biotherapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
